All news from Sri Lanka, Bhutan, Nepal and Bangladesh

New Approach against Anthrax and Plague: Dual Vaccine

A team of researchers has now engineered a virus nanoparticle vaccine against Bacillus anthracis and Yersinia pestis, tier 1 agents that pose serious threats to national security of the United States. B. anthracis and Y. pestis are the pathogens that cause anthrax and plague, respectively. The study is published in mBio, an open-access journal of the American Society for Microbiology.

New Findings: Mad Cow Disease found on Aberdeenshire Farm

Scotland has confirmed its first case of Mad Cow disease or Bovine Spongiform Encephalopathy (BSE) since 2018 on a cattle farm. The case was confirmed after a cow died. The numbers show that there have been a total of 16 cases in the United Kingdom over the past seven years.

BSE wrecked havoc among cattle in the 1980s and 1990s when it affected and killed thousands of cows. A further 4.4 million cattle were slaughtered to avoid the spread of the disease. The disease was first identified in 1995. The last recorded case in Wales was seen in 2015.

Early Clinical Trial Access: Barriers Still Exist

Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congress in Munich, you have highlighted the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and early childhood clinical trials, suggesting a need for more tailored approaches to give this patient population better access to therapeutic innovation.

Cystic fibrosis; New Hope Say Experts

A new triple-combination drug treatment being trialed at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosisMater Research Institute-University of Queensland (MRI-UQ) researcher Dr. Lucy Burr said these patients were enrolled in Phase 2 of the clinical trial, which aimed at treating the underlying cause of cystic fibrosis.

Breast Cancer: Statistical Method Estimates Long- and Short-term Risk of Recurrence

A statistical method could fill the gaps in the US cancer registry data to estimate the short- and long-term risk of recurrence of hormone receptor (HR) -positive and HR-negative breast cancers. 

The study found that while women diagnosed with HR-positive breast cancer have lower risk of progression to metastatic disease soon after the diagnosis, their risk persists for several years. In contrast, for women diagnosed with HR-negative disease, the risk of progression to metastatic disease is high after the diagnosis, but the long-term risk is lower than that for HR-positive disease. The study is published in the journal Cancer Epidemiology, Biomarkers & Prevention